Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04587479 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Jacobio Pharmaceuticals Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT04587479: Completed Phase 1 study, sponsored by Jacobio Pharmaceuticals Co..
NCT04587479 is a Phase 1 study that has completed, run by Jacobio Pharmaceuticals Co.. The registered enrollment target is 41 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04587479, a Phase 1 study, has completed, sponsored by Jacobio Pharmaceuticals Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.
Primary Outcome
Incidence of dose limiting toxicities (DLTs) in the dose escalation phase. A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first treatment cycle with JAB-8263
Interventions
- DRUG JAB-8263
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2024-10-31 |
| Phase | Phase 1 |
What the finished NCT04587479 record still lists
NCT04587479 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 1 intervention - of which JAB-8263 is the first listed.
NCT04587479 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04587479 about?
NCT04587479 is a clinical study titled "A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors". This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.
What is the current status of trial NCT04587479?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2020-11-23. Estimated completion is 2024-10-31.
What interventions are being tested in trial NCT04587479?
The interventions under investigation include: JAB-8263 (DRUG).
Who is sponsoring clinical trial NCT04587479?
This trial is sponsored by Jacobio Pharmaceuticals Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04587479's enrollment target sits among peer trials
41 1125th of 2000 higher than 871 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI